PRISMA—Efficacy and Safety of Vedolizumab for Inflammatory Bowel Diseases

Volume: 93, Issue: 28, Pages: e326 - e326
Published: Dec 1, 2014
Abstract
Vedolizumab is an anti-inflammatory monoclonal antibody that exclusively targets the α4β7 integrin. We aimed to systematically review the efficacy and safety of vedolizumab for patients with inflammatory bowel diseases (IBDs). PubMed, EMBASE, and the Cochrane Library were searched up to May 2014. Randomized controlled trials examining the efficacy or safety of vedolizumab in patients with IBDs were eligible for inclusion. Data were extracted...
Paper Details
Title
PRISMA—Efficacy and Safety of Vedolizumab for Inflammatory Bowel Diseases
Published Date
Dec 1, 2014
Journal
Volume
93
Issue
28
Pages
e326 - e326
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.